Introduction The loss of epithelial barrier function is a hallmark of IBD. TNFα is considered a key driver of IBD, directly causing barrier disfunction. Although TNFα-neutralizing therapy has been used for decades to treat IBD,...
Introduction Despite large scale technological and data-driven advances, efficacious and long-lasting treatments for chronic gut illnesses such as IBD, Crohn’s and Ulcerative Colitis (UC) appear to remain out of reach for the millions of sufferers...
The relationship between dysbiosis, inflammation and disease is a burgeoning area of research [reviewed in 1-4]. A recently published paper by Sinha and colleagues examines the role of dysbiosis in Ulcerative Colitis[5]. Their work highlights...
The intestinal epithelium is characterised by intense self-renewal which is accomplished by intestinal stem cells (ISCs), located at the base of the crypts. Beyond normal tissue homeostasis, these cells play a major role in the...
Inflammatory bowel disease (IBD) is a group of debilitating gastrointestinal (GI) disorders characterized by epithelial damage and chronic inflammation. Epithelial targeting aimed to repair and protect the epithelial barrier is central to current clinical practice....
The basis of maintaining a healthy gut is the tripartite communication between the intestinal epithelium, the mucosal immune system, and the intestinal microbiome. It is important to maintain conditions that allow appropriate responses by the...
